EdgeMarket › What Orbimed Advisors Llc reported owning
What Orbimed Advisors Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
5.0BPositions
112Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | 488.8M | 9.7% | 15.5M | 44.18 | +219.2% |
| ELVN Enliven Therapeutics, Inc. | 312.0M | 6.2% | 8.0M | 59.82 | +204.3% |
| LLY ELI LILLY & Co | 217.8M | 4.3% | 236.8K | 1,255.40 | +78.0% |
| SVA SINOVAC BIOTECH LTD | 184.5M | 3.7% | 2.7M | 6.47 | +0.0% |
| BSX BOSTON SCIENTIFIC CORP | 149.5M | 3.0% | 2.4M | 50.37 | -52.5% |
| SION Sionna Therapeutics, Inc. | 141.5M | 2.8% | 3.5M | 5.29 | -76.8% |
| AZN ASTRAZENECA PLC | 132.2M | 2.6% | 670.2K | 165.98 | — |
| MYGN MYRIAD GENETICS INC | 122.9M | 2.4% | 125.0M | 3.20 | -42.1% |
| MBX MBX Biosciences, Inc. | 108.6M | 2.2% | 3.6M | 66.33 | +386.6% |
| CRVS Corvus Pharmaceuticals, Inc. | 104.8M | 2.1% | 7.2M | 14.46 | +178.6% |
| ARGX ARGENX SE | 100.0M | 2.0% | 136.9K | 1,039.78 | +57.3% |
| EW Edwards Lifesciences Corp | 98.5M | 2.0% | 1.2M | 89.79 | +10.3% |
| ISRG INTUITIVE SURGICAL INC | 96.2M | 1.9% | 208.7K | 378.81 | -21.2% |
| CMPX Compass Therapeutics, Inc. | 80.5M | 1.6% | 15.2M | 2.40 | -13.7% |
| MRK Merck & Co., Inc. | 79.8M | 1.6% | 663.4K | 152.55 | +80.2% |
| GPCR Structure Therapeutics Inc. | 71.1M | 1.4% | 1.5M | 49.09 | +164.4% |
| AVBP ArriVent BioPharma, Inc. | 69.8M | 1.4% | 3.0M | 29.12 | +51.1% |
| IRON Disc Medicine, Inc. | 68.3M | 1.4% | 1.1M | 79.81 | +35.9% |
| SPRY ARS Pharmaceuticals, Inc. | 66.6M | 1.3% | 8.3M | 5.50 | -62.3% |
| CGON CG Oncology, Inc. | 64.2M | 1.3% | 948.3K | 79.81 | +212.6% |
| XENE Xenon Pharmaceuticals Inc. | 61.6M | 1.2% | 1.1M | 60.77 | +61.5% |
| SYK STRYKER CORP | 60.0M | 1.2% | 182.5K | 329.45 | -15.9% |
| BMY BRISTOL MYERS SQUIBB CO | 56.1M | 1.1% | 925.0K | 67.01 | +38.9% |
| MLYS Mineralys Therapeutics, Inc. | 55.6M | 1.1% | 2.1M | 25.65 | +65.7% |
| PRAX Praxis Precision Medicines, Inc. | 55.6M | 1.1% | 172.5K | 375.94 | +730.8% |
| PFE PFIZER INC | 54.7M | 1.1% | 1.9M | 28.07 | +10.6% |
| DYN Dyne Therapeutics, Inc. | 52.9M | 1.0% | 2.9M | 26.10 | +118.0% |
| NTRA Natera, Inc. | 52.4M | 1.0% | 262.0K | 332.03 | +106.7% |
| ABVX Abivax S.A. | 51.9M | 1.0% | 465.7K | 114.95 | +59.9% |
| UPB Upstream Bio, Inc. | 51.2M | 1.0% | 5.7M | 6.97 | -57.4% |
| DHR DANAHER CORP /DE/ | 50.4M | 1.0% | 265.8K | 218.85 | +3.5% |
| CAI Caris Life Sciences, Inc. | 50.2M | 1.0% | 2.8M | 26.27 | -25.1% |
| RCEL AVITA Medical, Inc. | 42.5M | 0.8% | 41.0M | 10.06 | +114.5% |
| ASND Ascendis Pharma A/S | 41.6M | 0.8% | 182.0K | 253.29 | +31.4% |
| STTK Shattuck Labs, Inc. | 40.5M | 0.8% | 6.3M | 7.53 | +645.5% |
| GH Guardant Health, Inc. | 40.2M | 0.8% | 435.2K | 170.69 | +191.8% |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | 39.4M | 0.8% | 119.0K | 236.22 | -48.5% |
| PRLD Prelude Therapeutics Inc | 37.3M | 0.7% | 10.9M | 6.63 | +531.4% |
| CRNX Crinetics Pharmaceuticals, Inc. | 36.3M | 0.7% | 999.0K | 84.69 | +191.1% |
| AXSM Axsome Therapeutics, Inc. | 36.2M | 0.7% | 213.9K | 207.77 | +77.6% |
| QURE uniQure N.V. | 34.9M | 0.7% | 2.1M | 48.37 | +212.5% |
| ORIC Oric Pharmaceuticals, Inc. | 34.1M | 0.7% | 2.7M | 14.20 | +49.3% |
| ELV Elevance Health, Inc. | 33.6M | 0.7% | 114.7K | 400.54 | +29.2% |
| RLMD RELMADA THERAPEUTICS, INC. | 32.8M | 0.7% | 4.7M | 4.63 | +655.9% |
| FBRX Forte Biosciences, Inc. | 31.0M | 0.6% | 1.2M | 76.92 | +554.1% |
| TRVI Trevi Therapeutics, Inc. | 29.3M | 0.6% | 2.5M | 17.96 | +142.0% |
| unmapped CUSIP 29664W105 | 29.0M | 0.6% | 10.6M | — | — |
| NPCE NeuroPace Inc | 27.6M | 0.5% | 2.1M | 14.03 | +62.0% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 27.3M | 0.5% | 314.1K | 110.00 | +11.4% |
| TMO THERMO FISHER SCIENTIFIC INC. | 22.9M | 0.5% | 46.5K | 629.27 | +27.2% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →